MedTrace Logo

Carboplatin in Castration-resistant Prostate Cancer

NCT02311764 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-01-23

No results posted yet for this study

Summary

Open label, non-randomised phase II clinical pilot study

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

Carboplatin

Carboplatin will be administered weekly

Sponsors & Collaborators

  • Teva Pharma

    collaborator INDUSTRY

  • University Hospital, Zürich

    collaborator OTHER

  • Aurelius Omlin

    lead OTHER

Principal Investigators

  • Aurelius G Omlin, MD · Cantonal Hospital St. Gallen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02311764 on ClinicalTrials.gov